Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Management of Regional Lymph Nodes in Patients with Merkel Cell Carcinoma Following a Positive Sentinel Node Biopsy: Less May be More, But is Either Enough?

Hruby G, Guminski A, Thompson JF.

Ann Surg Oncol. 2018 Nov 27. doi: 10.1245/s10434-018-7076-3. [Epub ahead of print] No abstract available.

PMID:
30483975
2.

Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.

Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, Epstein R, Blanksby A, Horvath L, Guminski A, Mahon K, Gedye C, Yin C, Stricker P, Joshua AM.

Clin Genitourin Cancer. 2018 Sep 27. pii: S1558-7673(18)30663-3. doi: 10.1016/j.clgc.2018.09.014. [Epub ahead of print]

PMID:
30425003
3.

Characteristics and outcomes of oncology unit patients requiring admission to an Australian intensive care unit.

Tan AC, Jacques SK, Oatley M, Guminski AD.

Intern Med J. 2018 Nov 8. doi: 10.1111/imj.14160. [Epub ahead of print]

PMID:
30411448
4.

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy.

Lim SY, Lee JH, Gide TN, Menzies AM, Guminski A, Carlino MS, Breen EJ, Yang JYH, Ghazanfar S, Kefford RF, Scolyer RA, Long GV, Rizos H.

Clin Cancer Res. 2018 Nov 8. pii: clincanres.2795.2018. doi: 10.1158/1078-0432.CCR-18-2795. [Epub ahead of print]

PMID:
30409824
5.

FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.

Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, Guminski AD, Long GV, Menzies AM.

Ann Oncol. 2018 Oct 1;29(10):2115-2120. doi: 10.1093/annonc/mdy330.

PMID:
30137228
6.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.

PMID:
29863979
7.

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA.

Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.

PMID:
29602646
8.

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators.

Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

PMID:
29477665
9.

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.

Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS.

JAMA Oncol. 2018 May 1;4(5):717-721. doi: 10.1001/jamaoncol.2017.5332.

PMID:
29423503
10.

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.

Tio M, Wang X, Carlino MS, Shivalingam B, Fogarty GB, Guminski AD, Lo S, Hong AM, Menzies AM, Long GV.

Pigment Cell Melanoma Res. 2018 Jul;31(4):509-515. doi: 10.1111/pcmr.12682. Epub 2018 Jan 10.

PMID:
29277979
11.

The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.

Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH.

Eur J Endocrinol. 2018 Feb;178(2):175-182. doi: 10.1530/EJE-17-0810. Epub 2017 Nov 29.

PMID:
29187509
12.

Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.

Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, Dirix L, Combemale P, Stratigos A, Plummer R, Castro H, Yi T, Mone M, Zhou J, Trefzer U, Kaatz M, Loquai C, Kudchadkar R, Sellami D, Dummer R.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):372-381. doi: 10.1111/jdv.14542. Epub 2017 Nov 6.

13.

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS.

Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17.

PMID:
28729151
14.

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS.

Br J Cancer. 2017 Jun 6;116(12):1558-1563. doi: 10.1038/bjc.2017.142. Epub 2017 May 18.

15.

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA.

Clin Cancer Res. 2017 Sep 1;23(17):5024-5033. doi: 10.1158/1078-0432.CCR-16-0698. Epub 2017 May 16.

16.

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program.

Parente P, Ng S, Parnis F, Guminski A, Gurney H.

Asia Pac J Clin Oncol. 2017 Dec;13(6):391-399. doi: 10.1111/ajco.12679. Epub 2017 May 10.

PMID:
28488360
17.

Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.

Crumbaker M, Guminski A, Gurney H, Sabanathan D, Wong S, Pavlakis N.

Asia Pac J Clin Oncol. 2018 Apr;14(2):e45-e49. doi: 10.1111/ajco.12686. Epub 2017 Apr 21.

PMID:
28429452
18.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H.

Ann Oncol. 2017 May 1;28(5):1130-1136. doi: 10.1093/annonc/mdx026.

PMID:
28327969
19.

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O.

Br J Cancer. 2017 Apr 11;116(8):e15. doi: 10.1038/bjc.2017.59. Epub 2017 Mar 21. No abstract available.

20.

Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.

Choong ES, Lo S, Drummond M, Fogarty GB, Menzies AM, Guminski A, Shivalingam B, Clarke K, Long GV, Hong AM.

Eur J Cancer. 2017 Apr;75:169-178. doi: 10.1016/j.ejca.2017.01.007. Epub 2017 Feb 23.

PMID:
28236768
21.

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.

Itchins M, Ascierto PA, Menzies AM, Oatley M, Lo S, Douraghi-Zadeh D, Harrington T, Maher R, Grimaldi AM, Guminski A.

Melanoma Res. 2017 Jun;27(3):243-250. doi: 10.1097/CMR.0000000000000343.

PMID:
28230715
22.

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.

Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, Carlino MS, Hong A, Long GV.

Oncoimmunology. 2016 Aug 19;5(9):e1214788. eCollection 2016.

23.

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, Kefford RF, Menzies AM, Long GV, Ascierto PA.

Br J Cancer. 2016 Nov 22;115(11):1280-1284. doi: 10.1038/bjc.2016.321. Epub 2016 Oct 6.

24.

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV.

Ann Oncol. 2017 Feb 1;28(2):368-376. doi: 10.1093/annonc/mdw443.

PMID:
27687304
25.

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD.

J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30.

26.

Sentinel node biopsy for melanoma: The medical oncology perspective.

Menzies AM, Atkinson VG, Brown MP, Carlino MS, Cebon J, Guminski A, Kefford RF, Long GV, McArthur G, McNeil CM, Millward M, Sandhu S.

Aust Fam Physician. 2015 Dec;44(12):875-6. No abstract available.

PMID:
27505912
27.

Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.

Kong BY, Menzies AM, Saunders CA, Liniker E, Ramanujam S, Guminski A, Kefford RF, Long GV, Carlino MS.

Pigment Cell Melanoma Res. 2016 Sep;29(5):572-7. doi: 10.1111/pcmr.12503. Epub 2016 Aug 4.

PMID:
27333363
28.

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.

Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O.

Br J Cancer. 2016 May 10;114(10):1084-9. doi: 10.1038/bjc.2016.107. Epub 2016 Apr 28.

29.

The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.

Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Cornélis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR.

J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5. doi: 10.1016/j.jaad.2016.02.1226. Epub 2016 Apr 7.

30.

Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients.

Charles KA, Harris BD, Haddad CR, Clarke SJ, Guminski A, Stevens M, Dodds T, Gill AJ, Back M, Veivers D, Eade T.

BMC Cancer. 2016 Feb 18;16:124. doi: 10.1186/s12885-016-2089-4.

31.

Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review.

Ahn MJ, D'Cruz A, Vermorken JB, Chen JP, Chitapanarux I, Dang HQ, Guminski A, Kannarunimit D, Lin TY, Ng WT, Park KU, Chan AT.

Oral Oncol. 2016 Feb;53:10-6. doi: 10.1016/j.oraloncology.2015.11.019. Epub 2015 Dec 19. Review.

32.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI.

JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.

PMID:
26633184
33.

Nonmelanoma Cutaneous Head and Neck Cancer and Merkel Cell Carcinoma: Current Concepts, Advances, and Controversies.

Porceddu SV, Veness MJ, Guminski A.

J Clin Oncol. 2015 Oct 10;33(29):3338-45. doi: 10.1200/JCO.2014.60.7333. Epub 2015 Sep 8. Review.

PMID:
26351348
34.

Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.

Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MM, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV.

Cancer. 2015 Nov 1;121(21):3826-35. doi: 10.1002/cncr.29586. Epub 2015 Jul 28.

35.

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R.

Lancet Oncol. 2015 Jun;16(6):716-28. doi: 10.1016/S1470-2045(15)70100-2. Epub 2015 May 14.

PMID:
25981810
36.

Neutrophil-to-lymphocyte ratio in head and neck cancer.

Haddad CR, Guo L, Clarke S, Guminski A, Back M, Eade T.

J Med Imaging Radiat Oncol. 2015 Aug;59(4):514-9. doi: 10.1111/1754-9485.12305. Epub 2015 Apr 23.

PMID:
25908427
37.

Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma.

Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, Zarate D, Simpson F, Porceddu SV.

Ann Oncol. 2014 Oct;25(10):2047-52. doi: 10.1093/annonc/mdu368. Epub 2014 Aug 4.

PMID:
25091317
38.

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

Chan MM, Haydu LE, Menzies AM, Azer MW, Klein O, Lyle M, Clements A, Guminski A, Kefford RF, Long GV.

Cancer. 2014 Oct 15;120(20):3142-53. doi: 10.1002/cncr.28851. Epub 2014 Jul 1.

39.

Acute Radiation Skin Toxicity Associated With BRAF Inhibitors.

Pulvirenti T, Hong A, Clements A, Forstner D, Suchowersky A, Guminski A, McNeil C, Hersey P, Fogarty G, Kefford R, Long GV, Wang W.

J Clin Oncol. 2016 Jan 20;34(3):e17-20. doi: 10.1200/JCO.2013.49.0565. Epub 2014 May 27. No abstract available.

PMID:
24868021
40.

Intra-arterial infusion and chemo-embolization for melanoma liver metastases.

Lodh S, Maher R, Guminski A.

J Surg Oncol. 2014 Mar;109(4):376-82. doi: 10.1002/jso.23551. Epub 2014 Feb 5. Review.

PMID:
24500702
41.

Intensity-modulated radiotherapy using simultaneous-integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: outcomes from a single-institution series.

Johnston M, Guo L, Back M, Guminski A, Lee A, Hanna C, Veivers D, Wignall A, Eade T.

J Med Imaging Radiat Oncol. 2013 Jun;57(3):356-63. doi: 10.1111/1754-9485.12033. Epub 2013 Jan 17.

PMID:
23721147
42.

Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis.

Cameron S, de Long LM, Hazar-Rethinam M, Topkas E, Endo-Munoz L, Cumming A, Gannon O, Guminski A, Saunders N.

Mol Cancer. 2012 Sep 28;11:74. doi: 10.1186/1476-4598-11-74.

43.

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.

Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, Minchin RF, Guminski A.

EMBO Mol Med. 2012 Aug;4(8):675-84. doi: 10.1002/emmm.201101131. Epub 2012 Jun 25. Review.

44.

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.

Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S, Dahler A, Hazar-Rethinam M, de Long LM, Wooley K, Guminski A, Saunders NA.

Br J Cancer. 2012 Jan 3;106(1):107-15. doi: 10.1038/bjc.2011.495. Epub 2011 Nov 24.

45.

Effect of the thymidylate synthase inhibitors on dUTP and TTP pool levels and the activities of DNA repair glycosylases on uracil and 5-fluorouracil in DNA.

Grogan BC, Parker JB, Guminski AF, Stivers JT.

Biochemistry. 2011 Feb 8;50(5):618-27. doi: 10.1021/bi102046h. Epub 2011 Jan 11.

46.

Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.

Kohli RM, Maul RW, Guminski AF, McClure RL, Gajula KS, Saribasak H, McMahon MA, Siliciano RF, Gearhart PJ, Stivers JT.

J Biol Chem. 2010 Dec 24;285(52):40956-64. doi: 10.1074/jbc.M110.177402. Epub 2010 Oct 6.

47.

Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases.

Endo-Munoz L, Cumming A, Rickwood D, Wilson D, Cueva C, Ng C, Strutton G, Cassady AI, Evdokiou A, Sommerville S, Dickinson I, Guminski A, Saunders NA.

Cancer Res. 2010 Sep 15;70(18):7063-72. doi: 10.1158/0008-5472.CAN-09-4291. Epub 2010 Sep 7.

48.

Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma.

Poth KJ, Guminski AD, Thomas GP, Leo PJ, Jabbar IA, Saunders NA.

Mol Cancer Ther. 2010 Aug;9(8):2430-9. doi: 10.1158/1535-7163.MCT-10-0258. Epub 2010 Aug 3.

49.

Tumor-initiating activity and tumor morphology of HNSCC is modulated by interactions between clonal variants within the tumor.

Cameron SR, Dahler AL, Endo-Munoz LB, Jabbar I, Thomas GP, Leo PJ, Poth K, Rickwood D, Guminski A, Saunders NA.

Lab Invest. 2010 Nov;90(11):1594-603. doi: 10.1038/labinvest.2010.131. Epub 2010 Jul 26.

50.

Predicting response to IL-2 therapy for metastatic melanoma.

Guminski AD, Thompson JF.

Expert Rev Anticancer Ther. 2009 Nov;9(11):1571-5. doi: 10.1586/era.09.131. No abstract available.

PMID:
19895241

Supplemental Content

Loading ...
Support Center